Human immunodeficiency virus type 1 Vpu and cellular TASK proteins suppress transcription of unintegrated HIV-1 DNA
© Emeagwali and Hildreth; licensee BioMed Central Ltd. 2012
Received: 17 May 2012
Accepted: 31 October 2012
Published: 19 November 2012
Unintegrated HIV-1 DNA serves as transcriptionally active templates in HIV-infected cells. Several host factors including NF-κβ enhance HIV-1 transcription. HIV-1 induced NF-κβ activation can be suppressed by viral protein U (Vpu). Interestingly HIV-1 Vpu shares amino acid homology with cellular Twik-related Acid Sensitive K+ (TASK) channel 1 and the proteins physically interact in cultured cells and AIDS lymphoid tissue. Furthermore, the first transmembrane domain of TASK-1 is functionally interchangeable with Vpu and like Vpu enhances HIV-1 release.
Here we further characterize the role of TASK channels and Vpu in HIV-1 replication. We demonstrate that both TASK channels and Vpu can preferentially inhibit transcription of unintegrated HIV-1 DNA. Interestingly, TASK-1 ion channel function is not required and suppression of HIV-1 transcription by TASK-1 and Vpu was reversed by overexpression of RelA (NF-κβ p65).
TASK proteins and Vpu suppress transcription of unintegrated HIV-1 DNA through an NF-κβ-dependent mechanism. Taken together these findings support a possible physiological role for HIV-1 Vpu and TASK proteins as modulators of transcription of unintegrated HIV-1 DNA genomes.
KeywordsHIV-1 Viral protein U Unintegrated HIV-1 DNA HIV-1 transcription Twik-related Acid Sensitive K+ proteins
Twik-related acid sensitive K channel
Viral protein U
unintegrated HIV DNA
inward rectifying K+ channel
nuclear Factor kappa-light-chain-enhancer of activated B cells
I kappa beta
beta-transducin repeat containing protein.
Human immunodeficiency virus type 1 (HIV-1) replication involves a series of highly orchestrated steps that are regulated by both viral and cellular factors. Like other retroviruses, HIV-1’s genome is reverse transcribed before the proviral DNA integrates into host cell chromatin. HIV-1 proviral DNA preferentially integrates into open transcriptionally active sites in the host cell chromatin where robust viral gene transcription can occur. Integration of HIV-1 DNA, mediated by viral integrase, allows the viral genome to persist throughout the lifespan of the cell. However, despite the critical role of integration in the lifecycle of all retroviruses, during the course of HIV-1 infection the majority of viral DNA remains unintegrated .
Unintegrated HIV-1 DNA (uDNA) is generated during virus replication and serves as DNA templates for transcription. The majority of viral uDNA genomes remain linear. Linear HIV-1 DNA, the substrate for integration, is found in both the cytoplasm and nucleus and can be degraded or modified by host factors [1–3]. uDNA can circularize by homologous recombination  or ligation of interrupted reverse transcription intermediates  to form 1-LTR circles. uDNA can also circularize by non-homologous end joining DNA repair events to form 2-LTR circles [6, 7]. In addition, formation of 1-LTR and 2-LTR circles can result from activity of host factors involved in DNA repair. Circular forms of the viral genome are found exclusively in the nucleus. Interestingly, the host restriction factor APOBEC3G has been shown to cause a 2-fold decrease in 2-LTR circle formation in cells infected with Δvif HIV-1 .
In HIV-1-infected patients, high levels of uDNA can be found in the blood, lymphoid tissues, and brain [1, 6, 9–12]. uDNA also accumulates in non-dividing cells such as macrophages and resting T cells but is lost in dividing cells through dilution during cell division [13–15]. Clinically, detection of high levels of uDNA in the brain is associated with development of AIDS dementia and correlates with a decline in CD4+ T cells. In addition, uDNA templates are increased in HIV-infected cells of patients given ART regimens with the integrase inhibitor, Raltegravir. The accumulation of uDNA in patients appears to be independent of viral load [16, 17].
Several studies have characterized important roles for uDNA with respect to HIV-1 infection [18–24]. Linear uDNA is the form used by HIV-1 integrase to incorporate the viral genome into host cell chromatin. uDNA can contribute to virus genetic diversity by providing templates for viral genome complementation of the integrated HIV-1 genome during virus assembly and production [25, 26]. Transcriptional activity in uDNA is lower than that of integrated genomes. However, early gene products of HIV-1 infection, Tat and Nef, are transcribed and translated in cells containing only uDNA [20, 24, 27, 28]. Nef protein production from uDNA is sufficient to promote T cell activation, down regulate CD4 and enhance HIV-1 infection . Tat, an important viral protein in HIV replication, is initially produced from uDNA. Tat production from uDNA transactivates the HIV-1 LTR of both uDNA and integrated HIV-1 DNA .
Transcription of uDNA is enhanced by viral protein R (Vpr) a late gene product of HIV-1 infection. Interestingly both virion-associated Vpr and newly synthesized Vpr preferentially increase transcription of nef from uDNA templates . Another late gene product of HIV-1 infection is viral protein U (Vpu). Vpu promotes the efficient release of virus particles from the cell surface, induces the degradation of CD4 in the ER and suppresses the activation of NF-κβ [31–33]. Vpu also restricts the function of several host proteins including tetherin and Twik-related Acid Sensitive K+ channel-1 (TASK-1) [34, 35]. TASK proteins are a part of the family of two-pore domain background potassium (K(2P)) channels.
TASK channels are widely expressed by many cell types and establish resting membrane potential and cell excitability. They are functional as dimers and have been shown to form homo- and heterodimers in vivo. Hsu et al. demonstrated that HIV-1 Vpu shows a high degree of sequence similarity to the first transmembrane domain of TASK-1 (Ttm1) . In addition, Vpu can self-assemble into homo-oligomeric complexes and form ion channels in lipid bilayers. Interestingly Vpu’s ion channel function is not required to antagonize CD317-mediated restriction of HIV release [37, 38]. In their study characterizing the homology between Vpu and the first transmembrane domain of TASK-1, Hsu et al. demonstrated that Vpu and Ttm1 were each capable of functional inhibition of the other. Furthermore it was found that cells infected with Vpu-deleted HIV-1, NL4-3 Udel, produced low levels of virus and this was reversed when Ttm1 was expressed in trans.
These observations suggest that some form of molecular piracy may have occurred during the evolution of HIV-1 infection. Here we demonstrate for the first time that TASK proteins and Vpu preferentially suppress transcription of uDNA. Our results have important implications for further understanding host-pathogen interactions that regulate HIV-1 replication and pathogenesis.
Overexpression of TASK-1 suppresses HIV-1 replication
Assembly and budding of progeny virions from infected cells comprise the late stages of HIV-1 biogenesis and are multi-step events driven by the viral protein Gag. Indeed, transient expression of Gag alone is sufficient for the formation of virus-like particles (VLPs) consistent with the central role of Gag in particle assembly and release. To evaluate the effect of TASK proteins on the late stages of the HIV-1 life cycle, particle release from 293T cells co-expressing Gag driven by a CMV promoter and TASK-1 was evaluated. We observed no difference in Gag-mediated VLP release from cells in the presence or absence of TASK-1 protein (Figure 1c, 1d). Similarly using provirus HIV-1 SG3 containing a neomycin phosphotransferase (NPT) gene under the transcriptional regulation of SV40 we observed no change in NPT protein levels with TASK protein expression while HIV-1 Gag protein under the control of the LTR promoter was significantly decreased (data not shown). These findings indicate that the effect of TASK proteins on HIV-1 replication is not due to inhibition of Gag assembly and release. Furthermore TASK protein expression preferientally suppresses gene transcription driven by the HIV-LTR but not transcription from CMV or SV40 promoters.
Since the late stages of virus replication were not affected by TASK protein overexpression we examined the effect of TASK protein expression on the earlier stages of HIV-1 replication. 293T cells were cotransfected with pNL4-3 and TASK-3 or empty vector. After 48 hours intracellular Gag from cell lysates was quantified with a capture p24 antigen ELISA. We found that overexpression of TASK proteins decreased intracellular Gag by over 83% (data not shown).
TASK-1 protein suppresses HIV-1 transcription
TASK channel function is not required for suppression of HIV-1 transcription
Both HIV-1 Vpu and TASK protein decrease HIV-1 transcription
To determine if the HIV-1 Tat protein was involved in suppression of HIV-1 transcription by TASK and Vpu, we co-transfected 293T cells with an HIV-1-LTR-GFP plasmid along with empty vector, TASK-1 or Vpu cDNA in trans and measured expression of HIV-1-LTR-dependent GFP by flow cytometry after 48 hours. The HIV-1-LTR-GFP plasmid does not include the tat gene and in the absence of Tat there was a low level of endogenous HIV LTR promoter activity. However as previously seen in Figures 2 and 4a both Vpu and TASK significantly suppressed HIV-1 transcription in the absence of Tat (Figure 4c). These results showed that Vpu and TASK-1 suppress HIV-1 transcription in a Tat-independent manner.
TASK and Vpu proteins preferentially suppress unintegrated HIV-1 DNA
TASK-1 and Vpu suppress HIV transcription in cells infected with Integrase defective virus
Vpu and TASK-1 suppress unintegrated HIV-1 DNA in an NFκβ-dependent manner
Hsu et al. showed that a cellular K+ channel TASK-1 is homologous to HIV-1 Vpu and that the first transmembrane domain of TASK-1 was functionally interchangeable with Vpu . They also observed that TASK-1 was able to inhibit HIV-1 release and appeared to function as an HIV-1 restriction factor. We wanted to follow up on this observation and examine potential mechanisms by which TASK proteins block HIV-1 replication. Using a combination of transfection experiments and infections by wildtype and integrase-defective virus, we obtained data indicating that Vpu and TASK proteins suppress transcription of HIV-1 genes. This effect was preferentially exerted on uDNA. The mechanism by which TASK and Vpu differentially suppress transcription from uDNA is not clear. We showed that the mechanism likely involves NF-κβ and it is not clear why this factor would have a differential effect on integrated versus uDNA. It is possible that other critical proteins required for transcription from uDNA but not integrated genomes are either sequestered or degraded in the presence of Vpu or TASK. Integrated HIV DNA as part of the cellular chromatin structure may require a different set of cellular factors for transcription compared to uDNA.
HIV-1 Vpu is a late gene product expressed after HIV-1 integration when sufficient levels of Rev is present for the production of unspliced and singly spliced genes . In addition to antagonizing the host protein tetherin, degrading CD4 and enhancing virus release, Vpu decreases both TNF-α and HIV-1-mediated activation of NF-κβ by inhibiting βTrCP-dependent degradation of Iκβ . Other viral proteins such as Vpr, Tat, and gp120 have also been shown to directly or indirectly affect NF-κβ regulation [42–46]. Prior to HIV-1 integration, uDNA produce early gene products: nef, rev and tat. After integration of HIV-1 proviral DNA, when sufficient Rev levels are present, Vpu mRNA is translated and the protein accumulates in infected cells. HIV-1 infection causes constitutive activation of NF-κβ [47–49], a host transcription activator that resides in the cytoplasm complexed to Iκβ. βTrCP-mediated degradation of Iκβ frees NFκβ to migrate into the nucleus where it can bind a variety of promoters including the HIV-1 LTR. Using immunoprecipitation studies, Hsu et. al demonstrated an association between Vpu, TASK-1 and βTrCP. They also showed that TASK-1 protein is degraded after infection in primary CD4+ T lymphocytes . These findings the led authors to speculate that Vpu may mediate the degradation of TASK-1 through the βTrCP ubiquitin ligase pathway similar to Vpu-mediated degradation of CD4 and Iκβ [32, 34]. Our findings with both functional and nonfunctional TASK proteins along with the previously described interaction between TASK-1 and βTrCP indicate that TASK-1 and Vpu may share a common mechanism of suppressing HIV-1 transcription: decreased NF-κβ activation by inhibiting βTrCP-dependent Iκβ degradation.
Bour et al. showed that overexpression of sub-genomic constructs expressing all HIV-1 proteins except Gag and Pol led to a moderate 3-fold activation of NF-κβ in the presence of Vpu and a 14-fold enhancement in the absence of Vpu . Similar results were obtained when full-length HIV-1 constructs were used. Thus Vpu negatively modulates of NF-κβ activation and this would lead to lower levels of HIV-1 transcription in some cell types. This data is consistent with results presented here where we demonstrate that suppression of HIV-1 transcription by Vpu and TASK proteins can be abrogated by overexpression of RelA. Interestingly, our results show that Vpu and TASK proteins exert their negative effect on HIV-1 transcription preferentially on uDNA. Our findings are not in conflict with those of Bour et al. since they used largely transfection-based studies to examine the effect of Vpu on NF-κβ activation. In such studies, proviral genomes remain unintegrated.
We also demonstrated that homologous TASK proteins profoundly suppressed HIV-1 transcription. TASK-1 and TASK-3 proteins are constitutively expressed in primary CD4+ T cells and contribute 40% of the K+ efflux needed to mediate Ca2+-dependent T cell effector function, namely T cell proliferation and the production of IFNγ and IL-2 . IFNγ induces TNFα production leading to NF-κβ activation and subsequently HIV-1 LTR mediated transcription. T cell effector function is a Ca2+ dependent immune response that also leads to the destruction of virally infected cells and the priming of neighboring T cells . TASK-mediated enhancement of Ca2+-dependent transcription of cytokines after HIV-1 infection may be a component of the host cell response to restrict HIV-1 replication. Since TASK proteins can suppress HIV-1 transcription and they play a role in generating critical cytokines needed to combat the virus, TASK proteins can be viewed as HIV-1 host restriction factors. This is consistent with the observation that after HIV-1 infection, Vpu leads to the degradation of TASK proteins . However, modulation of transcription from uDNA may be essential to efficient replication as this function is present in Vpu and therefore maintained by the virus.
Our data and model are not in conflict with the earlier studies of Wu and others showing efficient expression of early genes from episomal HIV DNA [20, 24, 30, 41, 51–54]. In our model, TASK, as a constitutively expressed cellular protein, would suppress expression of early genes from episomal DNA as part of the cellular response to the virus. TASK may represent the natural silencing mechanism and Vpu, which is able to cause degradation of TASK, may represent the virus’ mechanism for suppressing the cellular response. It is extremely intriguing, that the virus protein that is able to destroy the restricting protein (TASK) has the same activity itself. Thus, initially Vpu’s role may be to suppress TASK and then later it suppresses transcription from uDNA after sufficient early gene products have formed to drive expression from integrated DNA.
Our findings have important implications given the increased use of integrase inhibitors in antiretroviral therapy. In the presence of integrase inhibitors uDNA accumulates because more substrates are available for the non-homologous end joining pathways when integration is blocked [55, 56]. Although uDNA templates are transcriptionally active and can be suppressed by TASK protein, the presence of uDNA prior to integration has been associated with activation and productive infection in resting T-cells via expression of Tat and Nef from uDNA. When HIV-1 integration is blocked CD4, CCR5 and CXCR4 are down regulated by Nef, leading to a restriction of superinfection events [57–60]. In addition, HLA molecules recognized by helper  and cytotoxic T-cells are down regulated by Nef while HLA molecules that are recognized by natural killer cells are not affected by Nef [62–65]. Therefore early production of Nef from uDNA may be important for immune evasion by HIV-1 . In non-dividing cells with slower viral replication kinetics, such as macrophages, uDNA is biologically active and very stable. In these cells there is persistent transcription, primarily of early genes, of the uDNA. In infections with integrase defective lentiviral vectors in animal models, reservoirs of uDNA are relatively long lived [66, 67].
The regulation of uDNA is important since replication of integrase-defective viruses can be rescued by superinfection with wild type virus [26, 68]. Vpr promotes transcription from the uDNA, and after integration when Rev protein is present, transcripts from uDNA can be exported from the nucleus and translated. Therefore proteins encoded by uDNA can participate in virion assembly. Both RNA and protein products from uDNA can be packaged into virions, providing an opportunity for recombination and second round infections . This phenomenon could contribute meaningfully to the genetic diversity of HIV-1.
Materials and methods
Reagents, plasmids, and antibodies
TY191F , rodent TASK-1, rodent TASK-3 and IRK-1 expression plasmids were kind gifts from Dr. Douglas Bayliss (University of Virginia Charlottesville, VA). Human TASK-1, human TASK-3 and RelA-myc expression vectors were obtained from Origene (Rockville, MD). The Vpu-eGFP expression vector was a kind gift from Dr. Vasundhara Varthakavi (National Institutes of Health Bethesda, MD). Expression plasmids for codon-optimized Vpu (pcDNA-Vphu), phosphorylation defective mutant pcDNA-Vphu2/6 and a polyclonal antibody to Vpu were generous gifts from Klaus Strebel (National Institutes of Health, Bethesda, MD) and have been described elsewhere . A monoclonal antibody against HIV-1 Gag (GagM1) was generated in our laboratory. Commercially available antibodies against HIV-1 Gag KC57-RD1 (Beckman Coulter), TASK-1 (Chemicon) and β-tubulin (Santa Cruz Biotechnology) were used for immunoblotting experiments. Secondary antibodies (horseradish peroxidase-conjugated goat anti-rabbit (HRP-GAM), goat anti-mouse H+L (GAMH+L) and Fcγ specific (GAMFc) were obtained from Jackson ImmunoResearch Laboratories. Cell viability was measured using the Invitrogen fluorescence based LIVE/DEAD cell assay kit.
HIV-1 was prepared in 293T cells by transfection of plasmid DNA (pNL4-3-CFP and pNL4-3 D116N-YFP (kind gifts from Dr. David Levi) , and pNL4-3, pNL4-3-Udel (kind gift from Dr. Klaus Strebel)) using Lipofectamine (Invitrogen) per the manufacturer's instructions. The supernatants containing virus particles were harvested after 48hr of culture, filtered through a 0.2 micron filter and pelleted through a 20% sucrose cushion (100,000×g, 1hr). All virus preparations were treated with DNase I to remove plasmid DNA.
The Jurkat T cell line was obtained from the American Type Culture Collection (ATCC) and cultured in complete RPMI (cRPMI) (RPMI, 10 mM HEPES, 2 mM L-glutamine, 10% fetal bovine serum (FBS). The JLTRG cell line was obtained from Dr. Olaf Kutsch through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: JLTRG (Cat #11587). HEK 293T cell line was obtained from the ATCC and cultured in complete Dulbecco modified Eagle medium (cDMEM) DMEM, 10 mM HEPES, 2 mM L-glutamine, 10% fetal bovine serum (FBS). Cell viability was assessed by trypan blue exclusion.
Infections and transfections
HEK 293T cells were plated in 60-cm dishes (5 × 105 cells/2ml) and co-transfected with pNL4-3-Luc and TASK or Vpu cDNA. After washing and 48 hours of culture as above, the cells were lysed and lysates were analyzed for luciferase activity with the Promega luciferase assay kit as per manufacturer’s instructions. Jurkat cells were transfected with Vpu-eGFP or TASK-GFP DNA using the human T cell Nucleofector system (Amaxa, Gaithersburg, MD) per the manufacturer's instructions. After 6 hours cells were infected by spinoculation with 50ng of either wildtype NL4-3-CFP or integrase defective NL4-3D116N-YFP virus. Infection and transfection efficiencies were determined by either western blot analysis or flow cytometry. Briefly, for flow cytometry, cells were fixed with 2% paraformaldehyde, permeabilized using 0.1% saponin, and then stained with the mouse KC57-RD1 (anti-Gag) or an isotype-matched control antibody. Stained cells were analyzed on a Beckman FACS Calibur flow cytometer equipped with Cell Quest software. Viral infection and transfection rates were expressed as percentages of cells staining positively with the anti-p24 antibody or expressing CFP, YFP or GFP as appropriate.
Virus titer determinations
Two days after transfection with virus DNA constructs, HIV-1 Gag was measured in the cell culture supernatants and cell lysates using a capture ELISA.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting
Cell lysates were prepared by adding RIPA lysis buffer containing protease inhibitor cocktail (Roche) to cell pellets followed by incubation for 30 min on ice. Protein concentrations of cell lysates were determined using a bicinchoninic acid protein assay kit (Pierce-Rockford, IL). Equal amounts of protein were taken up in gel loading buffer and the samples were heated at 70°C for 10 min before loading onto a 4 - 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gradient gels (NuPAGE Novex Bis-Tris gels; Invitrogen). Proteins were transferred onto a Hybond-P polyvinylidene difluoride membrane (Amersham Biosciences, NJ) following manufacturers protocol. The membranes were blocked in 5% powdered milk in PBS, 0.1% Tween 20 and then probed with TASK-1 (1:1000), Vpu (1:000) or NF-κβ (1:500 dilution) for 60 min at 25°C . The membranes were then incubated for 60 min with horseradish peroxidase-conjugated, anti-mouse (1:10,000) or anti-rabbit (1:10,000) immunoglobulin G secondary antibodies (Promega, San Luis Obispo, CA) and developed using Super Signal chemiluminescence (Pierce). Bands were visualized on Denville Scientific film.
Total RNA was isolated using a Qiagen total RNA purification kit as per manufacturer’s instructions. RNA was treated with Qiagen’s DNase I and reverse-transcribed using the Invitrogen Superscript cDNA synthesis kit. The cDNA was treated with RNase H and then subjected to real time PCR with HIV-1 gene-specific primers. Real-time PCR conditions and primers to detect HIV-1 Nef-2 mRNA are described in detail elsewhere .
All experiments were performed three to six times, and representative experiments are shown. The Student t test was used to determine the statistical significance of the results.
This work was supported grants from NIH R01 HD40772 JEKH and F31 1F31AI081484-01 NE and NIH NCRR U54RR019192.
- Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183–188.PubMedView Article
- Sawyer SL, Malik HS: Positive selection of yeast nonhomologous end-joining genes and a retrotransposon conflict hypothesis. Proc Natl Acad Sci U S A 2006, 103:17614–17619.PubMedView Article
- Demogines A, East AM, Lee JH, Grossman SR, Sabeti PC, Paull TT, Sawyer SL: Ancient and recent adaptive evolution of primate non-homologous end joining genes. PLoS Genet 2010, 6:e1001169.PubMedView Article
- Farnet CM, Haseltine WA: Circularization of human immunodeficiency virus type 1 DNA in vitro. J Virol 1991, 65:6942–6952.PubMed
- Miller MD, Wang B, Bushman FD: Human immunodeficiency virus type 1 preintegration complexes containing discontinuous plus strands are competent to integrate in vitro. J Virol 1995, 69:3938–3944.PubMed
- Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M: Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991, 254:423–427.PubMedView Article
- Shoemaker C, Goff S, Gilboa E, Paskind M, Mitra SW, Baltimore D: Structure of a cloned circular Moloney murine leukemia virus DNA molecule containing an inverted segment: implications for retrovirus integration. Proc Natl Acad Sci U S A 1980, 77:3932–3936.PubMedView Article
- Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, Brown WL, Mansky LM, Gorelick RJ, Harris RS, et al.: Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 2007, 81:7099–7110.PubMedView Article
- Shaw GM, Hahn BH, Arya SK, Groopman JE, Gallo RC, Wong-Staal F: Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 1984, 226:1165–1171.PubMedView Article
- Luzuriaga K, McManus M, Catalina M, Mayack S, Sharkey M, Stevenson M, Sullivan JL: Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000, 74:6984–6991.PubMedView Article
- Pang S, Koyanagi Y, Miles S, Wiley C, Vinters HV, Chen IS: High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature 1990, 343:85–89.PubMedView Article
- Teo I, Veryard C, Barnes H, An SF, Jones M, Lantos PL, Luthert P, Shaunak S: Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS. J Virol 1997, 71:2928–2933.PubMed
- Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF: Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002, 76:4138–4144.PubMedView Article
- Butler SL, Johnson EP, Bushman FD: Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002, 76:3739–3747.PubMedView Article
- Brussel A, Mathez D, Broche-Pierre S, Lancar R, Calvez T, Sonigo P, Leibowitch J: Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS 2003, 17:645–652.PubMedView Article
- Cara A, Vargas J Jr, Keller M, Jones S, Mosoian A, Gurtman A, Cohen A, Parkas V, Wallach F, Chusid E, et al.: Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. Virology 2002, 292:1–5.PubMedView Article
- Carr JM, Cheney KM, Coolen C, Davis A, Shaw D, Ferguson W, Chang G, Higgins G, Burrell C, Li P: Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy. J Clin Microbiol 2007, 45:1288–1297.PubMedView Article
- Sakai H, Kawamura M, Sakuragi J, Sakuragi S, Shibata R, Ishimoto A, Ono N, Ueda S, Adachi A: Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol 1993, 67:1169–1174.PubMed
- Stevenson M, Haggerty S, Lamonica CA, Meier CM, Welch SK, Wasiak AJ: Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J Virol 1990, 64:2421–2425.PubMed
- Wiskerchen M, Muesing MA: Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol 1995, 69:376–386.PubMed
- Vandegraaff N, Kumar R, Burrell CJ, Li P: Kinetics of human immunodeficiency virus type 1 (HIV) DNA integration in acutely infected cells as determined using a novel assay for detection of integrated HIV DNA. J Virol 2001, 75:11253–11260.PubMedView Article
- Robinson HL, Zinkus DM: Accumulation of human immunodeficiency virus type 1 DNA in T cells: results of multiple infection events. J Virol 1990, 64:4836–4841.PubMed
- Swiggard WJ, O'Doherty U, McGain D, Jeyakumar D, Malim MH: Long HIV type 1 reverse transcripts can accumulate stably within resting CD4+ T cells while short ones are degraded. AIDS Res Hum Retroviruses 2004, 20:285–295.PubMedView Article
- Wu Y, Marsh JW: Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 2001, 293:1503–1506.PubMedView Article
- Kantor B, Ma H, Webster-Cyriaque J, Monahan PE, Kafri T: Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection. Proc Natl Acad Sci U S A 2009, 106:18786–18791.PubMedView Article
- Gelderblom HC, Vatakis DN, Burke SA, Lawrie SD, Bristol GC, Levy DN: Viral complementation allows HIV-1 replication without integration. Retrovirology 2008, 5:60.PubMedView Article
- Engelman A, Englund G, Orenstein JM, Martin MA, Craigie R: Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol 1995, 69:2729–2736.PubMed
- Kelly J, Beddall MH, Yu D, Iyer SR, Marsh JW, Wu Y: Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology 2008, 372:300–312.PubMedView Article
- Iyer SR, Yu D, Biancotto A, Margolis LB, Wu Y: Measurement of human immunodeficiency virus type 1 preintegration transcription by using Rev-dependent Rev-CEM cells reveals a sizable transcribing DNA population comparable to that from proviral templates. J Virol 2009, 83:8662–8673.PubMedView Article
- Poon B, Chen IS: Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. J Virol 2003, 77:3962–3972.PubMedView Article
- Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM: The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 1990, 64:621–629.PubMed
- Bour S, Perrin C, Akari H, Strebel K: The human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J Biol Chem 2001, 276:15920–15928.PubMedView Article
- Strebel K, Klimkait T, Maldarelli F, Martin MA: Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol 1989, 63:3784–3791.PubMed
- Hsu K, Seharaseyon J, Dong P, Bour S, Marban E: Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel. Mol Cell 2004, 14:259–267.PubMedView Article
- Neil SJ, Zang T, Bieniasz PD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425–430.PubMedView Article
- Czirjak G, Enyedi P: Formation of functional heterodimers between the TASK-1 and TASK-3 two-pore domain potassium channel subunits. J Biol Chem 2002, 277:5426–5432.PubMedView Article
- Bolduan S, Votteler J, Lodermeyer V, Greiner T, Koppensteiner H, Schindler M, Thiel G, Schubert U: Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317. Virology 2011, 416:75–85.PubMedView Article
- Ewart GD, Sutherland T, Gage PW, Cox GB: The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol 1996, 70:7108–7115.PubMed
- Hegle AP, Marble DD, Wilson GF: A voltage-driven switch for ion-independent signaling by ether-a-go-go K+ channels. Proc Natl Acad Sci U S A 2006, 103:2886–2891.PubMedView Article
- Ashmole I, Goodwin PA, Stanfield PR: TASK-5, a novel member of the tandem pore K+ channel family. Pflugers Arch 2001, 442:828–833.PubMedView Article
- Wu Y, Marsh JW: Early transcription from nonintegrated DNA in human immunodeficiency virus infection. J Virol 2003, 77:10376–10382.PubMedView Article
- Roux P, Alfieri C, Hrimech M, Cohen EA, Tanner JE: Activation of transcription factors NF-kappaB and NF-IL-6 by human immunodeficiency virus type 1 protein R (Vpr) induces interleukin-8 expression. J Virol 2000, 74:4658–4665.PubMedView Article
- Felzien LK, Woffendin C, Hottiger MO, Subbramanian RA, Cohen EA, Nabel GJ: HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator. Proc Natl Acad Sci U S A 1998, 95:5281–5286.PubMedView Article
- Demarchi F, Gutierrez MI, Giacca M: Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. J Virol 1999, 73:7080–7086.PubMed
- Clouse KA, Cosentino LM, Weih KA, Pyle SW, Robbins PB, Hochstein HD, Natarajan V, Farrar WL: The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. J Immunol 1991, 147:2892–2901.PubMed
- Hofman FM, Wright AD, Dohadwala MM, Wong-Staal F, Walker SM: Exogenous tat protein activates human endothelial cells. Blood 1993, 82:2774–2780.PubMed
- DeLuca C, Roulston A, Koromilas A, Wainberg MA, Hiscott J: Chronic human immunodeficiency virus type 1 infection of myeloid cells disrupts the autoregulatory control of the NF-kappaB/Rel pathway via enhanced IkappaBalpha degradation. J Virol 1996, 70:5183–5193.PubMed
- Asin S, Taylor JA, Trushin S, Bren G, Paya CV: Ikappakappa mediates NF-kappaB activation in human immunodeficiency virus-infected cells. J Virol 1999, 73:3893–3903.PubMed
- DeLuca C, Petropoulos L, Zmeureanu D, Hiscott J: Nuclear IkappaBbeta maintains persistent NF-kappaB activation in HIV-1-infected myeloid cells. J Biol Chem 1999, 274:13010–13016.PubMedView Article
- Meuth SG, Bittner S, Meuth P, Simon OJ, Budde T, Wiendl H: TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. J Biol Chem 2008, 283:14559–14570.PubMedView Article
- Cara A, Guarnaccia F, Reitz MS, Gallo RC, Lori F: Self-limiting, cell type-dependent replication of an integrase-defective human immunodeficiency virus type 1 in human primary macrophages but not T lymphocytes. Virology 1995, 208:242–248.PubMedView Article
- Lu R, Nakajima N, Hofmann W, Benkirane M, Jeang KT, Sodroski J, Engelman A: Simian virus 40-based replication of catalytically inactive human immunodeficiency virus type 1 integrase mutants in nonpermissive T cells and monocyte-derived macrophages. J Virol 2004, 78:658–668.PubMedView Article
- Nakajima N, Lu R, Engelman A: Human immunodeficiency virus type 1 replication in the absence of integrase-mediated dna recombination: definition of permissive and nonpermissive T-cell lines. J Virol 2001, 75:7944–7955.PubMedView Article
- Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA: HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990, 9:1551–1560.PubMed
- Kilzer JM, Stracker T, Beitzel B, Meek K, Weitzman M, Bushman FD: Roles of host cell factors in circularization of retroviral dna. Virology 2003, 314:460–467.PubMedView Article
- Zheng Y, Ao Z, Wang B, Jayappa KD, Yao X: Host protein Ku70 binds and protects HIV-1 integrase from proteasomal degradation and is required for HIV replication. J Biol Chem 2011, 286:17722–17735.PubMedView Article
- Michel N, Allespach I, Venzke S, Fackler OT, Keppler OT: The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4. Curr Biol 2005, 15:714–723.PubMedView Article
- Venzke S, Michel N, Allespach I, Fackler OT, Keppler OT: Expression of Nef downregulates CXCR4, the major coreceptor of human immunodeficiency virus, from the surfaces of target cells and thereby enhances resistance to superinfection. J Virol 2006, 80:11141–11152.PubMedView Article
- Wildum S, Schindler M, Munch J, Kirchhoff F: Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol 2006, 80:8047–8059.PubMedView Article
- Sloan RD, Donahue DA, Kuhl BD, Bar-Magen T, Wainberg MA: Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes. Retrovirology 2010, 7:44.PubMedView Article
- Sloan RD, Kuhl BD, Donahue DA, Roland A, Bar-Magen T, Wainberg MA: Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef. J Virol 2011, 85:2828–2836.PubMedView Article
- Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, Baltimore D: The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999, 10:661–671.PubMedView Article
- Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D: HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998, 391:397–401.PubMedView Article
- Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811–1815.PubMedView Article
- Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM: Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996, 2:338–342.PubMedView Article
- Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, Buch P, MacLaren RE, Anderson PN, Barker SE, et al.: Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006, 12:348–353.PubMedView Article
- Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, Petit C, Mallet J, Serguera C: Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A 2006, 103:17684–17689.PubMedView Article
- Wu Y: The second chance story of HIV-1 DNA: Unintegrated? Not a problem! Retrovirology 2008, 5:61.PubMedView Article
- Berg AP, Talley EM, Manger JP, Bayliss DA: Motoneurons express heteromeric TWIK-related acid-sensitive K+ (TASK) channels containing TASK-1 (KCNK3) and TASK-3 (KCNK9) subunits. J Neurosci 2004, 24:6693–6702.PubMedView Article
- Dowling D, Nasr-Esfahani S, Tan CH, O'Brien K, Howard JL, Jans DA, Purcell DF, Stoltzfus CM, Sonza S: HIV-1 infection induces changes in expression of cellular splicing factors that regulate alternative viral splicing and virus production in macrophages. Retrovirology 2008, 5:18.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.